Union européenne - français - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapénème sodique - infections bactériennes - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 et 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. la considération devrait être donnée à des recommandations officielles concernant l'utilisation appropriée des antibactériens.

Canada - français - Health Canada

sandoz canada incorporated - sunitinib - capsule - 12.5mg - sunitinib 12.5mg

Canada - français - Health Canada

sandoz canada incorporated - sunitinib - capsule - 25mg - sunitinib 25mg

Canada - français - Health Canada

sandoz canada incorporated - sunitinib - capsule - 37.5mg - sunitinib 37.5mg

Canada - français - Health Canada

sandoz canada incorporated - sunitinib - capsule - 50mg - sunitinib 50mg

Canada - français - Health Canada

auro pharma inc - sunitinib (malate de sunitinib) - capsule - 12.5mg - sunitinib (malate de sunitinib) 12.5mg

Canada - français - Health Canada

auro pharma inc - sunitinib (malate de sunitinib) - capsule - 25mg - sunitinib (malate de sunitinib) 25mg

Canada - français - Health Canada

auro pharma inc - sunitinib (malate de sunitinib) - capsule - 37.5mg - sunitinib (malate de sunitinib) 37.5mg

Canada - français - Health Canada

auro pharma inc - sunitinib (malate de sunitinib) - capsule - 50mg - sunitinib (malate de sunitinib) 50mg

Union européenne - français - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - tériparatide - osteoporosis; osteoporosis, postmenopausal - homéostasie du calcium - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.